{
    "root": "c6f1af69-8990-4e01-9157-5a688e734316",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pentazocine and naloxone",
    "value": "20240430",
    "ingredients": [
        {
            "name": "PENTAZOCINE HYDROCHLORIDE",
            "code": "A36BXO4PPX"
        },
        {
            "name": "NALOXONE HYDROCHLORIDE",
            "code": "F850569PQR"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "L11K75P92J"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 1 ALUMINUM LAKE",
            "code": "J9EQA3S2JM"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        }
    ],
    "indications": "pentazocine naloxone tablets indicated management pain severe enough require opioid analgesic alternative treatments inadequate . limitations risks addiction , abuse , misuse , opioids , occur duration , reserve pentazocine naloxone tablets patients alternative treatment options [ e.g . , non-opioid analgesics ] tolerated expected tolerated , provided adequate analgesia expected provide adequate analgesia . pentazocine naloxone tablets used extended period time unless pain remains severe enough require opioid analgesic alternative treatment options continue inadequate .",
    "contraindications": null,
    "warningsAndPrecautions": "pentazocine naloxone tablets , usp light green , scored , capsule shaped tablets debossed 395 left score , 50 0.5 right score watson reverse side supplied bottles 100. bottles 100 ………………………………… . . ndc 0591-0395-01 store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp . store pentazocine naloxone tablets , usp securely dispose properly [ precautions/information patients ] . manufactured india : watson pharma private limited verna , salcette goa 403 722 india manufactured : teva pharmaceuticals parsippany , nj 07054 rev . j 4/2024",
    "adverseReactions": "pentazocine naloxone tablets contraindicated patients : significant respiratory depression [ ] acute severe bronchial asthma unmonitored setting absence resuscitative equipment [ ] patients known suspected gastrointestinal obstruction , including paralytic ileus [ ] patients hypersensitivity either pentazocine , naloxone , formulation excipients ( e.g . , anaphylaxis ) [ ] .",
    "indications_original": "Pentazocine and Naloxone Tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.\n                  \n                     Limitations of Use\n                  \n                  Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosage or duration, reserve Pentazocine and Naloxone Tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]\n                  \n                     Have not been tolerated or are not expected to be tolerated,\n                     Have not provided adequate analgesia or are not expected to provide adequate analgesia.\n                  \n                  Pentazocine and Naloxone Tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.",
    "warningsAndPrecautions_original": "Pentazocine and Naloxone Tablets, USP are light green, scored, capsule shaped tablets debossed 395 to the left of the score, 50 over 0.5 to the right of the score and WATSON on the reverse side supplied in bottles of 100.\n                  Bottles of 100 ………………………………….. NDC 0591-0395-01\n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in the USP.\n                  Store Pentazocine and Naloxone Tablets, USP securely and dispose of properly [see \n                        PRECAUTIONS/Information for Patients\n                     ].\n                  Manufactured In India By:\n                     Watson Pharma Private Limited\n                     \nVerna, Salcette Goa 403 722 INDIA\n                  Manufactured For:\n                     Teva Pharmaceuticals\n                     \nParsippany, NJ 07054\nRev. J 4/2024",
    "adverseReactions_original": "Pentazocine and Naloxone Tablets are contraindicated in patients with:\n                  \n                     Significant respiratory depression [see \n                           WARNINGS\n                        ]\n                     \n                     Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see \n                           WARNINGS\n                        ]\n                     \n                     Patients with known or suspected gastrointestinal obstruction, including paralytic ileus [see \n                           WARNINGS\n                        ]\n                     \n                     Patients with hypersensitivity to either pentazocine, naloxone, or any of the formulation excipients (e.g., anaphylaxis) [see \n                           WARNINGS\n                        ]."
}